FINWIRES · TerminalLIVE
FINWIRES

Under Armour Faces Uncertainty Around Sales Recovery, BofA Securities Says

By

Under Armour (UA, UAA) faces uncertain sales recovery, with limited near-term visibility on a meaningful turnaround in North America demand and continued pressure on revenue trends, BofA Securities said in a note Wednesday.

Management's fiscal 2027 outlook assumes a stabilization year, with North America sales still declining in the low-single digits following a sharper drop in fiscal 2026, while overall guidance reflects a wide range of outcomes, according to the note.

BofA said that while adjusted operating income is expected to rise about 40% year over year at the midpoint, most of the improvement is driven by one-off tariff refunds, with underlying margin expansion more limited once those effects are excluded.

Analysts also highlighted ongoing SKU reductions, improved product focus, and lower discounting, but said there is still limited evidence these steps will drive a sustained demand recovery. The investment firm lowered its fiscal 2027 and 2028 earnings per share estimates by 58% and 46% to $0.10 and $0.17, respectively.

BofA maintained its neutral rating on the stock and lowered its price target to $6.40 from $8.

Price: $4.94, Change: $+0.04, Percent Change: +0.82%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP